Baca-Córdova A, Pérez-Jacobo F, Terán-González JÓ, González-Fernández NC, Reyes-Franco I, Martínez Ramos-Méndez M, Martínez-Zavala N, Hernández-Mendiola R, Enríquez-Peregrino KG, Gómez-Ana L, Alavez-Torres E

Language: Spanish
References: 19
Page: 40-49
PDF size: 218.72 Kb.

ABSTRACT

Background: Immune thrombocytopenia is a disease characterized by platelet destruction and impaired megakaryopoiesis. Definitive diagnosis of primary immune thrombocytopenia is by exclusion.
Objective: To assess adherence to established criteria regarding diagnostic approach and management decisions in patients diagnosed with immune thrombocytopenia.
Material and Method: A retrospective, descriptive, cross-sectional study in population older than 18 years with primary immune thrombocytopenia and treated at Hospital Central Norte de Petróleos Mexicanos, from January 2005 to December 2015.
Results: We included 88 patients, 67 (76%) had primary immune thrombocytopenia and 21 (24%) secondary immune thrombocytopenia. The most frequent conditions associated to secondary immune thrombocytopenia were systemic lupus erythematosus in 7%, followed by hepatitis C virus infection in 5.6%. Sixty-five patients (74%) met treatment initiation criteria as established on clinical consensus; the most frequent were steroids in 30 (34.1%) patients, and steroid + danazol in 20 (22.7%). At the time of analysis, 39 (60%) showed complete response, 20 (30%) incomplete response, and 6 (9%) no response. We found no difference in overall survival between the different treatment schemes prescribed, including splenectomy in relapsed patients.
Conclusiones: The frequency of secondary immune thrombocytopenia documented in our study reflects the relevance of the diagnostic approach in order to optimize management decisions and prevent complications.

REFERENCES

1. Mestanza M, Ariza R, Cardiel M, Alcocer J. Thrombocytopenic purpura as initial manifestation of systemic lupus erythematosus. J Rheumatol 1997 May;24(5):867-70.

2. Mc Milla R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hemathol 2007;44:S3-S11. doi: 10.1053/j.seminhematol.2007.11.002.

3. Provan D, Stasi R, Newland A, Blanchette V, Bolton-Maggs P, Bussel J, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2009;115(2):168-186. doi: 10.1182/ blood-2009-06-225565.

4. Neunert C, Lim W, Crowther M, Solberg L, Crowther M. The American Society of Hematology 2011 evidencebased practice guideline for immune thrombocytopenia. Blood 2011;117(16); 4190-4207. doi: 10.1182/ blood-2010-08-302984.

5. Sanz M, Vicente V, Fernández A, López M, Grande C, Jarque I, et al. Directrices de diagnóstico, tratamiento y seguimiento de la PTI: Sociedad Española de Hematología.

6. Guía de Práctica clínica Diagnóstico y Tratamiento de Púrpura Trombocitopénica Inmunológica, México; Secretaría de Salud, 2009.

7. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984 Dec;64(6):1179-83.

8. García LA, Muñoz A, Montiel A, Barragán R, Bejarano R, et al. Clinical analysis of 200 cases of idiopathic thrombocytopenic purpura. Rev Med Inst Mex Seguro Soc 2014 May- Jun;52(3):322-5.

9. Meillón L, García J, Gómez D, Gutiérrez G, Martínez C. Trombocitopenia inmune primaria (TIP) del adulto en México: características nacionales y su relación con la literatura internacional. Gac Méd Méx 2014;150:279-288.

10. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 Mar 12;113(11):2386-93. doi: 10.1182/ blood-2008-07-162503.

11. Wei Y, Ji X, Wang Y, Wang J, Yang E, Wang Z, et al. Highdose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 2015;127(3):296-302. doi: 10.1182/ blood-2015-07-659656.

12. Arnold D, Kelton J. Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 2007;44:S12-S23. doi: 10.1053/j.seminhematol. 2007.11.003.

13. Cines D, Liebman H, Stasi R. Pathobiology of Secondary Immune Thrombocytopenia. Semin Hematol 2008;46(1):S2-S14. https://dx.doi.org/10.1053%2Fj.seminhematol. 2008.12.005.

14. Rostami N, Keshtkar-Jahromi M, Rahnavardi M, Keshtkar- Jahromi M, FatemeH E. Effects of eradication of Helicobacter pylori on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura: A controlled trial. Am J Hematol 2008;83:376-381. doi: 10.1002/ajh.21125.

15. Liebman H. Other immune thrombocytopenias. Semin Hematol 2007;11(4):S24-S34. doi: 10.1053/j.seminhematol. 2007.11.004.

16. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012 Aug 2;120(5):960-9. doi: 10.1182/ blood-2011-12-309153.

17. Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, et al. Long-term follow-up after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol 2012;87:886-889. 10.1002/ajh.23272.

18. Khellaf M, Charles-Nelson A, Fai O, Terriou L, Villard J, Cheze S, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 2014;124(22):3228-3236. doi: 10.1182/blood-2014-06-582346.

19. Liu W, Gu X, Fu R, Li Y, Mingen Lv, Sun T, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb 2016;22(8):727-733. https://doi. org/10.1177%2F1076029615622002.